These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 29493385)
1. Use of next-generation sequencing in the CHAT study (acute HCV in HIV): effect of baseline resistance-associated NS3 variants on treatment failure. Jagjit Singh GK; Kaye S; Abbott JC; Boesecke C; Rockstroh J; McClure MO; Nelson M HIV Clin Trials; 2018 Apr; 19(2):46-51. PubMed ID: 29493385 [TBL] [Abstract][Full Text] [Related]
2. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. Sede MM; Laufer NL; Quarleri J Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594 [TBL] [Abstract][Full Text] [Related]
4. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764 [TBL] [Abstract][Full Text] [Related]
5. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies. Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509 [TBL] [Abstract][Full Text] [Related]
6. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555 [TBL] [Abstract][Full Text] [Related]
8. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study. Bartolini B; Selleri M; Garbuglia AR; Giombini E; Taibi C; Lionetti R; D'Offizi G; Capobianchi MR J Clin Virol; 2015 Nov; 72():60-5. PubMed ID: 26418073 [TBL] [Abstract][Full Text] [Related]
9. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227 [TBL] [Abstract][Full Text] [Related]
10. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225 [TBL] [Abstract][Full Text] [Related]
11. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy. Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343 [TBL] [Abstract][Full Text] [Related]
12. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Hara T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2013 Jun; 85(6):1028-36. PubMed ID: 23588728 [TBL] [Abstract][Full Text] [Related]
14. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir. Chui CK; Dong WW; Joy JB; Poon AF; Dong WY; Mo T; Woods CK; Beatty C; Hew H; Harrigan PR; Brumme CJ J Clin Microbiol; 2015 Sep; 53(9):2942-50. PubMed ID: 26135875 [TBL] [Abstract][Full Text] [Related]
15. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672 [TBL] [Abstract][Full Text] [Related]
16. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. Akuta N; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Saitoh S; Kobayashi M; Ikeda K; Kumada H J Med Virol; 2015 Apr; 87(4):609-18. PubMed ID: 25655809 [TBL] [Abstract][Full Text] [Related]
17. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin. McPhee F; Hernandez D; Zhou N Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868 [TBL] [Abstract][Full Text] [Related]
18. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Sulkowski MS; Sherman KE; Dieterich DT; Bsharat M; Mahnke L; Rockstroh JK; Gharakhanian S; McCallister S; Henshaw J; Girard PM; Adiwijaya B; Garg V; Rubin RA; Adda N; Soriano V Ann Intern Med; 2013 Jul; 159(2):86-96. PubMed ID: 23685940 [TBL] [Abstract][Full Text] [Related]
19. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study. Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R Virol J; 2013 Feb; 10():57. PubMed ID: 23409973 [TBL] [Abstract][Full Text] [Related]
20. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]